Andri Sanityoso Sulaiman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andri Sanityoso Sulaiman has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Cosmas Rinaldi Adithya Lesmana
Hepatobiliary Division, Internal Medicine Department Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia Jakarta Indonesia
6 shared publications Irsan Hasan
Hepatobiliary Division, Internal Medicine Department Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia Jakarta Indonesia
5 shared publications- Irsan Hasan
Hepatobiliary Division, Internal Medicine Department Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia Jakarta Indonesia
5 shared publications Rino Alvani Gani
Hepatobiliary Division, Internal Medicine Department Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia Jakarta Indonesia
5 shared publicationsDesti Rachmani
Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
4 shared publicationsJuferdy Kurniawan
Hepatobiliary Division, Internal Medicine Department Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia Jakarta Indonesia
4 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (8) , 1179-1180
Letter: Careful Interpretation of Lemborexant Efficacy and Safety in Patients With Cirrhosis. Authors' Reply
- 6 August 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (8) , 1179-1180
Open AccessLetter: Careful Interpretation of Lemborexant Efficacy and Safety in Patients With Cirrhosis. Authors' Reply
- Open Access
- 13 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0324671
Diagnostic concordance of GeneXpert HCV VL fingerstick and GeneXpert HCV viral load with RT-PCR in POCT settings among hemodialysis patients
Background: Hepatitis C virus (HCV) remains a significant global health concern, particularly among high-risk populations such as patients undergoing hemodialysis. Although nucleic acid testing (NAT) using RT-PCR remains the gold standard for HCV RNA detection, its centralized laboratory workflow limits accessibility. Point-of-care molecular testing (PoCT), such as the GeneXpert Fingerstick assay, offers a decentralized alternative for HCV RNA quantification. However, its analytical concordance with reference methods in Indonesian settings remains limited. Methods: This study was a cross-sectional analytical concordance study involving 57 patients with chronic kidney disease (CKD) undergoing hemodialysis at Cipto Mangunkusumo and Pelni Hospitals in Jakarta. Each participant underwent HCV RNA testing using three methods: GeneXpert HCV VL Fingerstick, GeneXpert HCV VL Plasma, and Cobas TaqMan RT-PCR (as the reference standard). Agreement among methods was assessed using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Cohen’s κ coefficient. Correlation for quantifiable values was evaluated using linear regression analysis. Results: Both GeneXpert methods showed perfect concordance with the Cobas TaqMan RT-PCR, with sensitivity, specificity, PPV, and NPV all at 100%. Agreement analysis yielded a Cohen’s κ of 1.000 ( p < 0.001) for both comparisons. Quantitative correlation between methods was also strong ( R² > 0.95). Conclusion: The GeneXpert HCV VL Fingerstick assay demonstrates excellent analytical agreement with conventional molecular testing and may serve as a simple, practical, decentralized alternative for monitoring HCV RNA in hemodialysis patients.
- 13 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0324671
Open AccessDiagnostic concordance of GeneXpert HCV VL fingerstick and GeneXpert HCV viral load with RT-PCR in POCT settings among hemodialysis patients
Background: Hepatitis C virus (HCV) remains a significant global health concern, particularly among high-risk populations such as patients undergoing hemodialysis. Although nucleic acid testing (NAT) using RT-PCR remains the gold standard for HCV RNA detection, its centralized laboratory workflow limits accessibility. Point-of-care molecular testing (PoCT), such as the GeneXpert Fingerstick assay, offers a decentralized alternative for HCV RNA quantification. However, its analytical concordance with reference methods in Indonesian settings remains limited. Methods: This study was a cross-sectional analytical concordance study involving 57 patients with chronic kidney disease (CKD) undergoing hemodialysis at Cipto Mangunkusumo and Pelni Hospitals in Jakarta. Each participant underwent HCV RNA testing using three methods: GeneXpert HCV VL Fingerstick, GeneXpert HCV VL Plasma, and Cobas TaqMan RT-PCR (as the reference standard). Agreement among methods was assessed using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Cohen’s κ coefficient. Correlation for quantifiable values was evaluated using linear regression analysis. Results: Both GeneXpert methods showed perfect concordance with the Cobas TaqMan RT-PCR, with sensitivity, specificity, PPV, and NPV all at 100%. Agreement analysis yielded a Cohen’s κ of 1.000 ( p < 0.001) for both comparisons. Quantitative correlation between methods was also strong ( R² > 0.95). Conclusion: The GeneXpert HCV VL Fingerstick assay demonstrates excellent analytical agreement with conventional molecular testing and may serve as a simple, practical, decentralized alternative for monitoring HCV RNA in hemodialysis patients.
- 1 July 2025
- Vol. 57 (3) , 314-320
Atherogenic Lipoprotein Profile in First-Degree Relatives of Individuals with Type 2 Diabetes Mellitus.
First-degree relatives (FDR) of individuals with type 2 diabetes mellitus (T2DM) are at higher risk of developing early metabolic disturbances, particularly insulin resistance and lipid metabolism abnormalities. These issues contribute to a greater predisposition to cardiovascular disease compared to the general population. Despite the significant contribution, there is limited information on the relationship between atherogenic lipoproteins and normotensive, normoglycemic young FDR in Indonesia. Therefore, this study aimed to evaluate the correlation between small dense low-density lipoprotein (sdLDL) levels and HOMA-IR in FDR with T2DM, as well as assess variation in sdLDL levels within FDR and non-FDR groups. This cross-sectional study analyzed secondary data from the Metabolic Endocrine and Diabetes Division of the Internal Medicine Department, Faculty of Medicine, Universitas Indonesia, and Cipto Mangunkusumo Hospital. The primary study, titled "Early Cardio-Metabolic Disorders in the First-Degree Relative Population of Type 2 Diabetes Mellitus," was expanded to include sdLDL measurements. Bivariate analysis and correlation tests were used to explore the relationship between sdLDL and HOMA-IR. The experiment included 125 subjects, consisting of 62 FDR and 63 non-FDR. Based on the results, sdLDL levels were significantly higher in the FDR group compared to the non-FDR group (31.42 (IQR 20.1-41.39) vs 21.05 (IQR 12.18-26.13) mg/dL, p<0.0001). However, no significant correlation was observed between sdLDL levels and HOMA-IR in the FDR group (r=0.059, p=0.649). This study showed a significant difference in sdLDL levels between FDR and non-FDR of T2DM patients. However, no correlation was found between sdLDL and HOMA-IR in the FDR group.
- 1 July 2025
- Vol. 57 (3) , 314-320
Atherogenic Lipoprotein Profile in First-Degree Relatives of Individuals with Type 2 Diabetes Mellitus.
First-degree relatives (FDR) of individuals with type 2 diabetes mellitus (T2DM) are at higher risk of developing early metabolic disturbances, particularly insulin resistance and lipid metabolism abnormalities. These issues contribute to a greater predisposition to cardiovascular disease compared to the general population. Despite the significant contribution, there is limited information on the relationship between atherogenic lipoproteins and normotensive, normoglycemic young FDR in Indonesia. Therefore, this study aimed to evaluate the correlation between small dense low-density lipoprotein (sdLDL) levels and HOMA-IR in FDR with T2DM, as well as assess variation in sdLDL levels within FDR and non-FDR groups. This cross-sectional study analyzed secondary data from the Metabolic Endocrine and Diabetes Division of the Internal Medicine Department, Faculty of Medicine, Universitas Indonesia, and Cipto Mangunkusumo Hospital. The primary study, titled "Early Cardio-Metabolic Disorders in the First-Degree Relative Population of Type 2 Diabetes Mellitus," was expanded to include sdLDL measurements. Bivariate analysis and correlation tests were used to explore the relationship between sdLDL and HOMA-IR. The experiment included 125 subjects, consisting of 62 FDR and 63 non-FDR. Based on the results, sdLDL levels were significantly higher in the FDR group compared to the non-FDR group (31.42 (IQR 20.1-41.39) vs 21.05 (IQR 12.18-26.13) mg/dL, p<0.0001). However, no significant correlation was observed between sdLDL levels and HOMA-IR in the FDR group (r=0.059, p=0.649). This study showed a significant difference in sdLDL levels between FDR and non-FDR of T2DM patients. However, no correlation was found between sdLDL and HOMA-IR in the FDR group.
- Open Access
Diagnostic Performance of GeneXpert HCV VL Finger Stick and GeneXpert HCV Viral Load Compared to RT-PCR in POCT settings : Establishing the Diagnosis of Chronic Hepatitis C in Hemodialysis Patients
Background The most widely utilized method for detecting HCV RNA is Nucleic Acid Testing (NAT) via RT PCR. In response to the need for more accessible and faster testing, particularly in high risk populations, an accessible method : Point of Care Molecular Testing (PoCT). International studies have demonstrated the use of fingerstick samples with this PoCT molecular method among injecting drug users in prisons, where HCV RNA PoCT exhibited a sensitivity of 98.4% for detecting viral loads (>4 IU/mL), and 100% sensitivity for quantifiable viral loads (≥10, 1000, and 3000 IU/mL), with a specificity of 100%. This PoCT testing is also a key element in the WHO’s strategy for achieving the Hepatitis elimination target by 2030. However, its application in Indonesia remains limited, and as such, the efficacy of this simple testing approach has yet to be fully evaluated in comparison to real-time PCR. Method This study is a diagnostic test with a cross-sectional design. There were 57 CKD on Hd patients in Cipto Mangunkusumo and Pelni Hospital tested by GeneXpert Fingerstick, Plasma and confimerd by PCR Cobas Taqman Result The probability test comparing the Fingerstick, GeneXpert, and Cobas Taqman 96 platforms yielded a p-value of Conclusion The GeneXpert fingerstick POCT may serve as a simple and reliable point-of-care method for detecting hepatitis C in patients with chronic kidney disease undergoing hemodialysis
Open AccessDiagnostic Performance of GeneXpert HCV VL Finger Stick and GeneXpert HCV Viral Load Compared to RT-PCR in POCT settings : Establishing the Diagnosis of Chronic Hepatitis C in Hemodialysis Patients
Background The most widely utilized method for detecting HCV RNA is Nucleic Acid Testing (NAT) via RT PCR. In response to the need for more accessible and faster testing, particularly in high risk populations, an accessible method : Point of Care Molecular Testing (PoCT). International studies have demonstrated the use of fingerstick samples with this PoCT molecular method among injecting drug users in prisons, where HCV RNA PoCT exhibited a sensitivity of 98.4% for detecting viral loads (>4 IU/mL), and 100% sensitivity for quantifiable viral loads (≥10, 1000, and 3000 IU/mL), with a specificity of 100%. This PoCT testing is also a key element in the WHO’s strategy for achieving the Hepatitis elimination target by 2030. However, its application in Indonesia remains limited, and as such, the efficacy of this simple testing approach has yet to be fully evaluated in comparison to real-time PCR. Method This study is a diagnostic test with a cross-sectional design. There were 57 CKD on Hd patients in Cipto Mangunkusumo and Pelni Hospital tested by GeneXpert Fingerstick, Plasma and confimerd by PCR Cobas Taqman Result The probability test comparing the Fingerstick, GeneXpert, and Cobas Taqman 96 platforms yielded a p-value of Conclusion The GeneXpert fingerstick POCT may serve as a simple and reliable point-of-care method for detecting hepatitis C in patients with chronic kidney disease undergoing hemodialysis
- 1 April 2024
- Vol. 56 (2) , 185-190
The Role of Genedrive in Point of Care Method For Hepatitis C Elimination in Hemodialysis Center
Background: Point of care is laboratory testing conducted close to the site of the patient. Point of care assessment is essential to detect and treat the hepatitis C virus in a single visit. The potential use of Genedrive extends to remote areas and key populations Therefore, there is a need for a simple, and cost-effective examination of methods, such as Genedrive. Genedrive is a rapid and low-cost diagnostic tool for the identification and treatment selection of infectious diseases. The World Health Organization targets to eliminate hepatitis by 2030, which decreases infections by 90%, and decreases deaths by 65%. Point of care could play a significant role in contributing to the elimination of hepatitis C. Chronic kidney disease (CKD) patients on hemodialysis are among the population at risk of hepatitis C due to nosocomial transmission. This study aimed to assess the role of Genedrive in measuring hepatitis C in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Methods: This study used a cross-sectional design. There were 64 CKD on Hd patients in Cipto Mangunkusumo Hospital tested by Genedrive. ROC analysis was conducted to assess significant hepatitis C among chronic kidney disease on hemodialysis. Results: The calculated detection limit of Genedrive was 3.1x10(3) IU/mL. Genedrive HCV assay showed 90.6% sensitivity, 96.8% specificity, 92% negative predictive value, and 97% positive predictive value to detect HCV, 10.36 positive likelihood ratio, and 0.09 negative likelihood ratio. Conclusion: Genedrive could be a simple and reliable point of care method to detect hepatitis C with chronic kidney disease on hemodialysis.
- 1 April 2024
- Vol. 56 (2) , 185-190
The Role of Genedrive in Point of Care Method For Hepatitis C Elimination in Hemodialysis Center
Background: Point of care is laboratory testing conducted close to the site of the patient. Point of care assessment is essential to detect and treat the hepatitis C virus in a single visit. The potential use of Genedrive extends to remote areas and key populations Therefore, there is a need for a simple, and cost-effective examination of methods, such as Genedrive. Genedrive is a rapid and low-cost diagnostic tool for the identification and treatment selection of infectious diseases. The World Health Organization targets to eliminate hepatitis by 2030, which decreases infections by 90%, and decreases deaths by 65%. Point of care could play a significant role in contributing to the elimination of hepatitis C. Chronic kidney disease (CKD) patients on hemodialysis are among the population at risk of hepatitis C due to nosocomial transmission. This study aimed to assess the role of Genedrive in measuring hepatitis C in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Methods: This study used a cross-sectional design. There were 64 CKD on Hd patients in Cipto Mangunkusumo Hospital tested by Genedrive. ROC analysis was conducted to assess significant hepatitis C among chronic kidney disease on hemodialysis. Results: The calculated detection limit of Genedrive was 3.1x10(3) IU/mL. Genedrive HCV assay showed 90.6% sensitivity, 96.8% specificity, 92% negative predictive value, and 97% positive predictive value to detect HCV, 10.36 positive likelihood ratio, and 0.09 negative likelihood ratio. Conclusion: Genedrive could be a simple and reliable point of care method to detect hepatitis C with chronic kidney disease on hemodialysis.
- Open Access
- 31 December 2023
- Published by Universitas Indonesia in Jurnal Penyakit Dalam Indonesia
- Vol. 10 (4) , 3
Kombinasi Sofosbuvir-Ledipasvir dan Sofosbuvir- Daclatasvir pada Pengobatan Pasien Hepatitis C di Indonesia
Introduction. Direct-acting antivirals (DAAs) has been developed for treatment hepatitis C virus (HCV). Therapy of HCV using DAA has shown high sustained virologic response (SVR) and shortening duration of therapy. Sofosbuvir-ledipasvir (SOF/LDV) is fixed dose combination tablet of DAAs which recommended for genotype 1, 4, 5, and 6 infected patients. In developing countries, SOF/LDV still can be used as cost-effective regimen in all genotype compared with sofosbuvir-daclatasvir (SOF/ DCV). This study aimed to evaluate the efficacy of combination sofosbuvir-ledipasvir in all genotypes of HCV patients compared with available DAA in Indonesia (sofosbuvir- daclatasvir). Methods. A retrospective study was conducted among patients who received HCV therapy in Klinik Hati and Cipto Mangunkusumo Hospital during January until December 2017. Demographic data, baseline characteristics virus, and baseline characteristics laboratory were collected from medical record. Quantitative polymerase chain reaction (PCR) for HCV RNA were assessed at the end point of study. The efficacy of SOF/LDV and SOF/DCV were carried out by sustained virological response at 12 weeks (SVR-12). Results. A total of 214 HCV patients were include in this study. Sixty-nine patients treated with SOF/LDV, whereas 145 patients treated with SOF/DCV. In group of SOF/LDV, 20 (29%) patients had an experience therapy, 9 (13%) received 24-week therapy, 26 (37.7%) patients observed with cirrhosis. In group of SOF/DCV, 24 (16.6%) patients had an experience therapy, 38 (26.2%) received 24-week therapy, 41 (28.3%) patients observed with cirrhosis. The patients were dominated by HCV genotype 1 in both of group SOF/LDV and SOF/DCV (63.7% vs. 67.6%). All patients had undetected HCV RNA virus after the combination therapy of SOF/LDV, with the SVR-12 rate was 69 (100%) patients. Meanwhile, SVR-12 rate was achieved in 142 (97.9%) patients in group SOF/DCV. Conclusion. SOF/LDV is effective in all genotypes of HCV patients and the cost fix dose combination of SOF/LDV more affordable to patients in developing countries compared with SOF/DCV regimen.
- 31 December 2023
- Published by Universitas Indonesia in Jurnal Penyakit Dalam Indonesia
- Vol. 10 (4) , 3
Open AccessKombinasi Sofosbuvir-Ledipasvir dan Sofosbuvir- Daclatasvir pada Pengobatan Pasien Hepatitis C di Indonesia
Introduction. Direct-acting antivirals (DAAs) has been developed for treatment hepatitis C virus (HCV). Therapy of HCV using DAA has shown high sustained virologic response (SVR) and shortening duration of therapy. Sofosbuvir-ledipasvir (SOF/LDV) is fixed dose combination tablet of DAAs which recommended for genotype 1, 4, 5, and 6 infected patients. In developing countries, SOF/LDV still can be used as cost-effective regimen in all genotype compared with sofosbuvir-daclatasvir (SOF/ DCV). This study aimed to evaluate the efficacy of combination sofosbuvir-ledipasvir in all genotypes of HCV patients compared with available DAA in Indonesia (sofosbuvir- daclatasvir). Methods. A retrospective study was conducted among patients who received HCV therapy in Klinik Hati and Cipto Mangunkusumo Hospital during January until December 2017. Demographic data, baseline characteristics virus, and baseline characteristics laboratory were collected from medical record. Quantitative polymerase chain reaction (PCR) for HCV RNA were assessed at the end point of study. The efficacy of SOF/LDV and SOF/DCV were carried out by sustained virological response at 12 weeks (SVR-12). Results. A total of 214 HCV patients were include in this study. Sixty-nine patients treated with SOF/LDV, whereas 145 patients treated with SOF/DCV. In group of SOF/LDV, 20 (29%) patients had an experience therapy, 9 (13%) received 24-week therapy, 26 (37.7%) patients observed with cirrhosis. In group of SOF/DCV, 24 (16.6%) patients had an experience therapy, 38 (26.2%) received 24-week therapy, 41 (28.3%) patients observed with cirrhosis. The patients were dominated by HCV genotype 1 in both of group SOF/LDV and SOF/DCV (63.7% vs. 67.6%). All patients had undetected HCV RNA virus after the combination therapy of SOF/LDV, with the SVR-12 rate was 69 (100%) patients. Meanwhile, SVR-12 rate was achieved in 142 (97.9%) patients in group SOF/DCV. Conclusion. SOF/LDV is effective in all genotypes of HCV patients and the cost fix dose combination of SOF/LDV more affordable to patients in developing countries compared with SOF/DCV regimen.
- Open Access
- 30 September 2023
- Published by Universitas Indonesia in Jurnal Penyakit Dalam Indonesia
- Vol. 10 (3) , 2
Perlemakan Hati Non-Alkoholik dan Risiko Fibrosis Hati pada Pasien Hepatitis B Kronik
Introduction. Prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing throughout the world due to sedentary lifestyle and dietary habit, including in patients with chronic hepatitis B (CHB). In several studies, advanced of liver disease were more likely observed among those CHB patients with NAFLD. NAFLD might increase the risk of liver disease progression in CHB patients, but prior investigations were still limited. This study aimed to determine the association between NAFLD and risk of liver fibrosis in CHB patients. Methods. All patients with positive serum hepatitis B surface antigen in the Hepatobilier Data Registry, Cipto Mangunkusumo Hospital, were included in this study. Based on abdominal ultrasonography, patients were divided into two group (group I: non-NAFLD – hepatitis B patients vs. group II: NAFLD – hepatitis B patients). Data demographic and clinical examination were collected. Significant liver fibrosis was defined as stage liver fibrosis above 7 kPa (≥ F2). Logistic regression was used to identify NAFLD as risk factor for significant fibrosis. Variables were expressed as prevalence odd ratio (POR) with 95% CI. P values <0.05 were considered statistically significant. Results. Among 130 hepatitis B patients, 45 patients (34.6%) were diagnosed with NAFLD. Of 45 patients in group II, 36 patients (80%) had significant liver fibrosis. It was observed that a higher percentage of patients in group II were HBeAg negative compared to those in group I (66.7% vs. 35.9%; p=0.038). Furthermore, group II also displayed higher levels of liver stiffness compared to group I (12.22 (8.6 kPa) vs. 8.57 (7.8 kPa); p 0.016). In multivariate analysis, NAFLD was significantly associated with significant liver fibrosis (POR: 5.87; CI95%: 2.48 – 13.86; p < 0.001) after adjusted with HBeAg status. Conclusion. NAFLD associated with the higher risk of liver fibrosis in patients with hepatitis B. Modification of lifestyle and potential therapeutic intervention may help in reducing the progression of liver fibrosis.
- 30 September 2023
- Published by Universitas Indonesia in Jurnal Penyakit Dalam Indonesia
- Vol. 10 (3) , 2
Open AccessPerlemakan Hati Non-Alkoholik dan Risiko Fibrosis Hati pada Pasien Hepatitis B Kronik
Introduction. Prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing throughout the world due to sedentary lifestyle and dietary habit, including in patients with chronic hepatitis B (CHB). In several studies, advanced of liver disease were more likely observed among those CHB patients with NAFLD. NAFLD might increase the risk of liver disease progression in CHB patients, but prior investigations were still limited. This study aimed to determine the association between NAFLD and risk of liver fibrosis in CHB patients. Methods. All patients with positive serum hepatitis B surface antigen in the Hepatobilier Data Registry, Cipto Mangunkusumo Hospital, were included in this study. Based on abdominal ultrasonography, patients were divided into two group (group I: non-NAFLD – hepatitis B patients vs. group II: NAFLD – hepatitis B patients). Data demographic and clinical examination were collected. Significant liver fibrosis was defined as stage liver fibrosis above 7 kPa (≥ F2). Logistic regression was used to identify NAFLD as risk factor for significant fibrosis. Variables were expressed as prevalence odd ratio (POR) with 95% CI. P values <0.05 were considered statistically significant. Results. Among 130 hepatitis B patients, 45 patients (34.6%) were diagnosed with NAFLD. Of 45 patients in group II, 36 patients (80%) had significant liver fibrosis. It was observed that a higher percentage of patients in group II were HBeAg negative compared to those in group I (66.7% vs. 35.9%; p=0.038). Furthermore, group II also displayed higher levels of liver stiffness compared to group I (12.22 (8.6 kPa) vs. 8.57 (7.8 kPa); p 0.016). In multivariate analysis, NAFLD was significantly associated with significant liver fibrosis (POR: 5.87; CI95%: 2.48 – 13.86; p < 0.001) after adjusted with HBeAg status. Conclusion. NAFLD associated with the higher risk of liver fibrosis in patients with hepatitis B. Modification of lifestyle and potential therapeutic intervention may help in reducing the progression of liver fibrosis.
- 30 March 2023
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (6) , 557-564
Diagnostic performance of Mac-2-binding protein glycosylation isomer (M2BPGi) as a liver fibrosis marker in chronic hepatitis C patients with chronic kidney disease on hemodialysis
Background/aim Liver fibrosis assessment is essential to determine the initiation, duration, and evaluation of chronic hepatitis C treatment. Therefore, the study aimed to assess the role of Mac-2-binding protein glycosylation isomer (M2BPGi) as a biomarker to measure liver fibrosis in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Methods This study used a cross-sectional design. Serum M2BPGi level and transient elastography results were evaluated in 102 chronic hepatitis C patients with CKD on HD, 36 CKD on HD patients, and 48 healthy controls. ROC analysis was conducted to identify the optimal cutoff values to assess significant fibrosis and cirrhosis among chronic hepatitis C patients with CKD on HD. Results In chronic hepatitis C patients with CKD on HD, the level of serum M2BPGi had a moderately significant correlation with transient elastography (r = 0.447, p < 0.001). The median serum M2BPGi was higher among CKD on HD patients compared to healthy controls (1.260 COI vs. 0.590 COI, p < 0.001) and was even higher in chronic hepatitis C patients with CKD on HD compared to CKD on HD group (2.190 COI vs. 1.260 COI, p < 0.001). It is also increased according to the severity of liver fibrosis: 1.670 COI, 2.020 COI, and 5.065 COI for F0–F1, significant fibrosis, and cirrhosis, respectively. The optimal cutoff values for diagnosing significant fibrosis and cirrhosis were 2.080 and 2.475 COI, respectively. Conclusion Serum M2BPGi could be a simple and reliable diagnostic tool for evaluating cirrhosis in chronic hepatitis C patients with CKD on HD.
- 30 March 2023
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (6) , 557-564
Diagnostic performance of Mac-2-binding protein glycosylation isomer (M2BPGi) as a liver fibrosis marker in chronic hepatitis C patients with chronic kidney disease on hemodialysis
Background/aim Liver fibrosis assessment is essential to determine the initiation, duration, and evaluation of chronic hepatitis C treatment. Therefore, the study aimed to assess the role of Mac-2-binding protein glycosylation isomer (M2BPGi) as a biomarker to measure liver fibrosis in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Methods This study used a cross-sectional design. Serum M2BPGi level and transient elastography results were evaluated in 102 chronic hepatitis C patients with CKD on HD, 36 CKD on HD patients, and 48 healthy controls. ROC analysis was conducted to identify the optimal cutoff values to assess significant fibrosis and cirrhosis among chronic hepatitis C patients with CKD on HD. Results In chronic hepatitis C patients with CKD on HD, the level of serum M2BPGi had a moderately significant correlation with transient elastography (r = 0.447, p < 0.001). The median serum M2BPGi was higher among CKD on HD patients compared to healthy controls (1.260 COI vs. 0.590 COI, p < 0.001) and was even higher in chronic hepatitis C patients with CKD on HD compared to CKD on HD group (2.190 COI vs. 1.260 COI, p < 0.001). It is also increased according to the severity of liver fibrosis: 1.670 COI, 2.020 COI, and 5.065 COI for F0–F1, significant fibrosis, and cirrhosis, respectively. The optimal cutoff values for diagnosing significant fibrosis and cirrhosis were 2.080 and 2.475 COI, respectively. Conclusion Serum M2BPGi could be a simple and reliable diagnostic tool for evaluating cirrhosis in chronic hepatitis C patients with CKD on HD.
- 15 February 2023
- Published by Springer Nature in Hepatology International
- Vol. 17 (4) , 989-999
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure
Background and aims Early identification of non-response to steroids is critical in patients with autoimmune hepatitis (AIH) causing acute-on-chronic liver failure (ACLF). We assessed if this non-response can be accurately identified within first few days of treatment. Methods Patients with AIH-ACLF without baseline infection/hepatic encephalopathy were identified from APASL ACLF research consortium (AARC) database. Diagnosis of AIH-ACLF was based mainly on histology. Those treated with steroids were assessed for non-response (defined as death or liver transplant at 90 days for present study). Laboratory parameters, AARC, and model for end-stage liver disease (MELD) scores were assessed at baseline and day 3 to identify early non-response. Utility of dynamic SURFASA score [− 6.80 + 1.92*(D0-INR) + 1.94*(∆%3-INR) + 1.64*(∆%3-bilirubin)] was also evaluated. The performance of early predictors was compared with changes in MELD score at 2 weeks. Results Fifty-five out of one hundred and sixty-five patients (age—38.2 ± 15.0 years, 67.2% females) with AIH-ACLF [median MELD 24 (IQR: 22–27); median AARC score 7 (6–9)] given oral prednisolone 40 (20–40) mg per day were analyzed. The 90 day transplant-free survival in this cohort was 45.7% with worse outcomes in those with incident infections (56% vs 28.0%, p = 0.03). The AUROC of pre-therapy AARC score [0.842 (95% CI 0.754–0.93)], MELD [0.837 (95% CI 0.733–0.94)] score and SURFASA score [0.795 (95% CI 0.678–0.911)] were as accurate as ∆MELD at 2 weeks [0.770 (95% CI 0.687–0.845), p = 0.526] and better than ∆MELD at 3 days [0.541 (95% CI 0.395, 0.687), p < 0.001] to predict non-response. Combination of AARC score > 6, MELD score > 24 with SURFASA score ≥ − 1.2, could identify non-responders at day 3 (concomitant— 75% vs either − 42%, p < 0.001). Conclusion Baseline AARC score, MELD score, and the dynamic SURFASA score on day 3 can accurately identify early non-response to steroids in AIH-ACLF.
- 15 February 2023
- Published by Springer Nature in Hepatology International
- Vol. 17 (4) , 989-999
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure
Background and aims Early identification of non-response to steroids is critical in patients with autoimmune hepatitis (AIH) causing acute-on-chronic liver failure (ACLF). We assessed if this non-response can be accurately identified within first few days of treatment. Methods Patients with AIH-ACLF without baseline infection/hepatic encephalopathy were identified from APASL ACLF research consortium (AARC) database. Diagnosis of AIH-ACLF was based mainly on histology. Those treated with steroids were assessed for non-response (defined as death or liver transplant at 90 days for present study). Laboratory parameters, AARC, and model for end-stage liver disease (MELD) scores were assessed at baseline and day 3 to identify early non-response. Utility of dynamic SURFASA score [− 6.80 + 1.92*(D0-INR) + 1.94*(∆%3-INR) + 1.64*(∆%3-bilirubin)] was also evaluated. The performance of early predictors was compared with changes in MELD score at 2 weeks. Results Fifty-five out of one hundred and sixty-five patients (age—38.2 ± 15.0 years, 67.2% females) with AIH-ACLF [median MELD 24 (IQR: 22–27); median AARC score 7 (6–9)] given oral prednisolone 40 (20–40) mg per day were analyzed. The 90 day transplant-free survival in this cohort was 45.7% with worse outcomes in those with incident infections (56% vs 28.0%, p = 0.03). The AUROC of pre-therapy AARC score [0.842 (95% CI 0.754–0.93)], MELD [0.837 (95% CI 0.733–0.94)] score and SURFASA score [0.795 (95% CI 0.678–0.911)] were as accurate as ∆MELD at 2 weeks [0.770 (95% CI 0.687–0.845), p = 0.526] and better than ∆MELD at 3 days [0.541 (95% CI 0.395, 0.687), p < 0.001] to predict non-response. Combination of AARC score > 6, MELD score > 24 with SURFASA score ≥ − 1.2, could identify non-responders at day 3 (concomitant— 75% vs either − 42%, p < 0.001). Conclusion Baseline AARC score, MELD score, and the dynamic SURFASA score on day 3 can accurately identify early non-response to steroids in AIH-ACLF.
- 1 October 2022
- Vol. 54 (4) , 567-573
Diagnostic Performance of Mac-2-Binding Protein Glycosylation Isomer (M2BPGi), compared to Transient Elastography to Assess Liver Stiffness in Treatment Naive Chronic Hepatitis C Patients
Background: Liver fibrosis is an essential factor in the management of Hepatitis C virus infection. Its assessment is crucial in decision-making regarding the therapeutic decisions, and the patients' follow up. However, the established liver measurement methods have several limitations. Therefore, this study aims to assess the role of Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) as a novel biomarker to measure liver stiffness in treatment naive Chronic Hepatitis C Indonesian patients. Methods: This study used a cross-sectional design to determine the correlation between serum M2BPGi and the degree of liver stiffness, Transient Elastrography, and differences in serum M2BPGi levels in chronic hepatitis C patients. Serum M2BPGi level and Transient Elastography results were evaluated in 56 Chronic Hepatitis C patients and 48 healthy controls. Pearson correlation analysis was conducted to find the correlation between the level of M2BPGi and Transient Elastography result. ROC analysis was conducted to find the optimum cut-off to assess fibrosis's degree among Chronic Hepatitis C Patients. Results: The level of serum M2BPGi and Transient Elastography result was strongly correlated with the median level of serum M2BPGi. It was also significantly higher among Chronic Hepatitis C Patients than among healthy controls (r: 0.708, p= F4) was 3.770 COI (AUC: 89.3%). Conclusion: Serum M2BPGi was a reliable diagnostic tool for identifying liver fibrosis in Indonesian patients with Chronic Hepatitis C.
- 1 October 2022
- Vol. 54 (4) , 567-573
Diagnostic Performance of Mac-2-Binding Protein Glycosylation Isomer (M2BPGi), compared to Transient Elastography to Assess Liver Stiffness in Treatment Naive Chronic Hepatitis C Patients
Background: Liver fibrosis is an essential factor in the management of Hepatitis C virus infection. Its assessment is crucial in decision-making regarding the therapeutic decisions, and the patients' follow up. However, the established liver measurement methods have several limitations. Therefore, this study aims to assess the role of Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) as a novel biomarker to measure liver stiffness in treatment naive Chronic Hepatitis C Indonesian patients. Methods: This study used a cross-sectional design to determine the correlation between serum M2BPGi and the degree of liver stiffness, Transient Elastrography, and differences in serum M2BPGi levels in chronic hepatitis C patients. Serum M2BPGi level and Transient Elastography results were evaluated in 56 Chronic Hepatitis C patients and 48 healthy controls. Pearson correlation analysis was conducted to find the correlation between the level of M2BPGi and Transient Elastography result. ROC analysis was conducted to find the optimum cut-off to assess fibrosis's degree among Chronic Hepatitis C Patients. Results: The level of serum M2BPGi and Transient Elastography result was strongly correlated with the median level of serum M2BPGi. It was also significantly higher among Chronic Hepatitis C Patients than among healthy controls (r: 0.708, p= F4) was 3.770 COI (AUC: 89.3%). Conclusion: Serum M2BPGi was a reliable diagnostic tool for identifying liver fibrosis in Indonesian patients with Chronic Hepatitis C.